Allergan subsidiary Vitae Pharmaceuticals granted Syndax Pharmaceuticals exclusive global rights to menin-MLL fusion oncogene inhibitors to treat patients with acute leukemia who have chromosomal rearrangements in the MLL gene. The deal grants Allergan $5 million upfront plus milestones and royalty fees.
An RFP Planning Guide Just for Oncology Sponsors Explore key cost drivers for oncology studies, such as: impact of geography, uncovering project management variations, and how timeline impacts cost savings. Download this complimentary eBook from Novella Clinical: RFP Guide to Oncology Clinical Trials.
The FDA will assess AstraZeneca's Imfinzi, or durvalumab, as a treatment for locally advanced, stage 3, unresectable non-small cell lung cancer that has not progressed following platinum-based chemoradiation.
The European Medicines Agency accepted into its PRIME priority medicines program Ignyta's entrectinib, which is being developed to treat adult and pediatric patients with NTRK-positive, locally advanced or metastatic solid tumors with disease progression after previous treatment and those with no other acceptable therapeutic options.
Suven Life Sciences received a Singapore product patent to develop treatments for patients with neurodegenerative diseases such as Parkinson's, schizophrenia, Alzheimer's, Huntington's and attention-deficit/hyperactivity disorder.
7 keys: Put real-world evidence into action Life sciences organizations need to know how their therapies work in the real world once clinical trials end. And these seven key components to standardizing real-world data and analytics platforms are how they get started. Read the paper, Institutionalizing Real World Evidence.
Takeda Pharmaceutical agreed to collaborate with HemoShear Therapeutics to discover, explore and develop targets for the possible treatment of liver diseases, including nonalcoholic steatohepatitis. The deal gives Takeda exclusive access to HemoShear's REVEAL-Tx platform for fatty liver diseases and grants HemoShear undisclosed upfront payments and research funding, plus $470 million in milestone payments and royalties.
A follow-on funding raised $80 million for Abeona Therapeutics. The company has an ongoing Phase I/II study of its mucopolysaccharidosis IIIA candidate ABO-102 and plans to initiate a late-stage study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa by next year.
Access award-winning solutions from Nikon! BIO preferred partner, Nikon, has won the 2017 iF Design Award, a globally recognized award sponsored by iF International Forum Design GmbH since 1953. Access these distinguished solutions!
Gene editing -- a practice that lets scientists add or subtract traits without introducing foreign DNA -- could be a key to feeding the world, according to top executives from Monsanto and DowDuPont. "We can do in six months now what used to take us six or seven years," said James Collins Jr., chief operating officer of DowDuPont's agriculture division.
BIO's newest industry offering: BIO One-on-One Partnering™ during the J.P. Morgan annual health care conference, Jan. 7-11, 2018, is the most cost-effective way to make valuable connections in the biotech and pharma industries without traveling the world. Communicate directly with prospective biotech investors and senior business and scientific management executives attending BIO's portfolio of events, and schedule meetings in BIO's meeting space at the San Francisco Marriott Marquis. BIO is pleased offer complimentary access to BIO One-on-One Partnering™ during JPM to make it easier and more affordable to partner in downtown San Francisco. Sign up today.
Make no little plans; they have no magic to stir men's blood. ... Make big plans; aim high in hope and work.
Daniel Burnham, architect and urban designer
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at email@example.com.